The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.
- Memantine (Ebixa)Drug
Intervention Desc: Beside the usual treatment for ischemic stroke this group will be treated by memantine. ARM 1: Kind: Experimental Label: Memantine Description: Patients with ischemic stroke in MCA territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
- Placebo Drug
Intervention Desc: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks. ARM 1: Kind: Experimental Label: Placebo Description: Patients with ischemic stroke in MCA territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
|Type||Measure||Time Frame||Safety Issue|
|Primary||Investigation of neurological deficit by NIHSS(National institute of health scale score)||7 days||No|
|Primary||Investigation of disability by mRS(modified Rankin scale)||7 days||No|
|Secondary||Investigation of neurological deficit by NIHSS||28 days||No|
|Secondary||Investigation of disability by mRS||28 days||No|
|Primary||Investigation of neurological deficit||7 days||No|
|Primary||Investigation of disability||7 days||No|